DexCom, Inc. $DXCM Stake Reduced by Cwm LLC

Cwm LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 163,282 shares of the medical device company’s stock after selling 2,862 shares during the quarter. Cwm LLC’s holdings in DexCom were worth $14,253,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in DexCom by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after buying an additional 925,882 shares during the last quarter. Jennison Associates LLC boosted its position in DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock worth $718,632,000 after acquiring an additional 2,879,489 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after acquiring an additional 1,868,241 shares during the period. Nuveen LLC acquired a new position in DexCom during the 1st quarter worth $554,893,000. Finally, Raymond James Financial Inc. boosted its position in DexCom by 21.8% during the 1st quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock worth $229,117,000 after acquiring an additional 601,088 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares of the company’s stock, valued at $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Mizuho boosted their price target on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 16th. William Blair upgraded DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Canaccord Genuity Group reiterated a “buy” rating and set a $106.00 price target on shares of DexCom in a research report on Monday, September 29th. Piper Sandler boosted their price target on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Finally, Oppenheimer lowered DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $97.42.

DexCom Trading Up 0.1%

Shares of DexCom stock opened at $65.20 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm has a market cap of $25.57 billion, a price-to-earnings ratio of 45.28, a price-to-earnings-growth ratio of 1.37 and a beta of 1.47. The business has a fifty day simple moving average of $74.20 and a 200-day simple moving average of $77.70. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company’s revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.